Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye scans could spot Diabetes-Related vision damage years early

NCT ID NCT07705321

Knowledge-focused Sponsor: University of Athens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study uses a non-invasive eye scan called OCTA to examine tiny blood vessels in the retina of adults with type 1 diabetes. The goal is to detect early signs of diabetic retinopathy, a leading cause of vision loss, before symptoms appear. Researchers will measure vessel density and other microvascular changes to better understand how diabetes affects the eyes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Optical coherence tomography angiography (OCTA) imaging
What this could lead to
If successful, this could enable earlier detection of diabetic retinopathy, potentially preventing vision loss through timely intervention.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve outcomes. The findings may not translate into routine clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with Type 1 diabetes mellitus, with or without clinically diagnosed diabetic retinopathy, recruited from the 2nd Department Ophthalmology outpatient clinics with and without diabetic retinopathy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 years or older. 2. Diagnosis of Type 1 diabetes mellitus (T1DM) according to the American Diabetes Association (ADA) criteria. 3. Ability and willingness to provide written informed consent. Exclusion Criteria: 1. Active uveitis or other intraocular inflammatory disease. 2. Uncontrolled glaucoma 3. High myopia (spherical equivalent refractive error \>5.0 diopters) 4. History of ocular trauma. 5. History of intraocular surgery within the previous 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes type 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Diabetes Complications diabetic retinopathy type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes type 1 Diabetic complications Diabetic retinopathy Microvascular circulation Retinal microvascular disease

Contacts and locations

Locations

  • 2nd Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens

    Athens, 12462, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.